
Swiss Noema Pharma raises CHF54m in Series A financing
It is one of the largest Series A rounds in Europe: Led by Sofinnova Partners and Polaris Partners, rare neurological diseases start-up Noema Pharma...

1,800+ experts will join the Global Bioeconomy Summit
First editions of the summit took place in Berlin in 2015 and 2018, this year it will be delivery fully virtually. The digital conference event...

BI initiates Phase II testing of COVID-19 drug
A new potential weapon against severe complications such as ARDS caused by the new coronavirus SARS-CoV-2 have been advanced by Boehringer Ingelheim...

Transgene reports clinical results of TG4001 plus avelumab
Combination of TG4001 and Merck KGaA’s checkpoint inhibitor avelumab demonstrated anti-tumour activity in patients with previously treated recurrent...

Bioinvent AB licences BI-1206 to CASI Pharmaceuticals
Cancer antibody specialist BioInvent International AB has granted the exclusive rights to market its anti-FcγRIIB antibody, BI-1206, in China,...

Polyphor AG bags funding for murepavadin
Swiss Polyphor AG (Allschwil) is developing its lead Outer Membrane Protein Targeting Antibiotic (OMPTA) candidate inhaled murepavadin against...

LSP reports first closing of dementia fund
The LSP Dementia Fund is the first fund globally dedicated to fight neurodegenerative diseases with help of drug and medtech solutions. The fund will...